Faruqi & Faruqi, LLP Launches An Investigation Against Cantel Medical Corp. For Potential Breaches Of Fiduciary Duties By Its Board Of Directors (CMN)
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Cantel Medical Corp. (“Cantel” or the “Company”) (NYSE: CMN) for potential breaches of fiduciary duties in connection with their conduct in seeking shareholders’ approval of an amendment to the Company’s Certificate of Incorporation.
Specifically, in the Proxy Statement filed by the Company with the Securities and Exchange Commission on November 28, 2012, the Board of Directors recommends that Cantel’s shareholders vote to approve an amendment to the Company’s Certificate of Incorporation to increase the number of authorized shares of common stock from 30,000,000 to 75,000,000. The issuance of the additional shares could have a severe dilutive effect on the shares of Cantel’s common stock.
If you own common stock in Cantel and wish to obtain additional information and protect your investments free of charge, please contact Juan E. Monteverde, Esq. either via e-mail at firstname.lastname@example.org or by telephone at (877) 247-4292 or (212) 983-9330.
Please tell us about yourself by completing the form below and we will provide you with additional
information at no cost to you on how to join the Class Action.
* The submission of this form does not create an attorney-client relationship.
Faruqi & Faruqi, LLP
369 Lexington Avenue 10th Floor
New York, NY 10017
Tel: (212) 983-9330
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.